Selected article for: "alprostadil effect and OA model"
Author: Yan, Xiujuan; Li, Yingxiu; Choi, Yun Ho; Wang, Chongyang; Piao, Yihua; Ye, Jing; Jiang, Jingzhi; Li, Liangchang; Xu, Huixian; Cui, Qingsong; Yan, Guanghai; Jin, Minggen
Title: Protective Effect and Mechanism of Alprostadil in Acute Respiratory Distress Syndrome Induced by Oleic Acid in Rats
  • Document date: 2018_10_8
    • ID: 7ea7ur3b_28
    Snippet: The effect of alprostadil on the production of the pro-inflammatory mediators TNF-a and IL-1ß was also analyzed by Western blot at 3 h after administration of OA. OA administration caused a significant increase in TNFa and IL-1b expression in the lung tissues when compared with the control group ( Figure 4A-4C; p<0 .05). Alprostadil (2.5, 5, and 10 μg/kg) administration caused an obviously decrease in the expression of TNF-a and IL-1b in the lu.....
    Document: The effect of alprostadil on the production of the pro-inflammatory mediators TNF-a and IL-1ß was also analyzed by Western blot at 3 h after administration of OA. OA administration caused a significant increase in TNFa and IL-1b expression in the lung tissues when compared with the control group ( Figure 4A-4C; p<0 .05). Alprostadil (2.5, 5, and 10 μg/kg) administration caused an obviously decrease in the expression of TNF-a and IL-1b in the lung tissue when compared with the OA model group. These results indicate that alprostadil inhibits the production of pro-inflammatory mediators and protects rats from OA-induced lung inflammation. Alprostadil suppresses MAPKs and NF-kB signaling pathways in OA-induced ARDS rats NF-kB and MAPK signaling pathways play key roles in OAinduced ARDS pathogenesis [36, 37] ; therefore, we investigated whether alprostadil could affect these pathways.

    Search related documents:
    Co phrase search for related documents
    • lung tissue and OA model: 1, 2, 3
    • lung tissue and OA model group: 1, 2, 3
    • lung tissue and pathway affect: 1
    • lung tissue and pathway signaling: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • lung tissue and pro inflammatory mediator: 1
    • lung tissue and significant increase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • lung tissue and TNF expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • lung tissue and western blot: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lung tissue expression and OA administration: 1, 2
    • lung tissue expression and OA model: 1, 2
    • lung tissue expression and OA model group: 1, 2
    • lung tissue expression and pathway signaling: 1, 2, 3, 4
    • lung tissue expression and significant increase: 1, 2, 3, 4, 5
    • lung tissue expression and TNF expression: 1, 2, 3
    • lung tissue expression and western blot: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • NF kB mapk and OA model: 1
    • NF kB mapk and OA model group: 1
    • NF kB mapk and TNF expression: 1
    • NF kB mapk and western blot: 1